TB-500+BPC-157 10 mg+10 mg PEN

One-Peptides TB-500+BPC-157 PEN – peptide blend in a pre-dissolved pen

TB-500+BPC-157 PEN 10 mg is a research reagent (Research Use Only) in the form of a pre-dissolved pen. The pen is the physical format of the reagent – it may look similar to pharmaceutical pen medicines (Ozempic, Mounjaro), but TB-500 and BPC-157 are not registered medicines in any jurisdiction. Label: “For research use only. Not for human use”. Athletes subject to anti-doping control: TB-500 (Thymosin Beta-4) is on the WADA Prohibited List year-round (S2).

In the regenerative-peptide literature, two molecules appear together more often than any other pair: TB-500 (a Thymosin Beta-4 fragment) and BPC-157 (a cytoprotective pentadecapeptide derived from gastric-juice protective proteins). The first modulates the actin cytoskeleton and cell migration, while the second acts on the NO/cGMP axis, VEGF and growth factors. The complementarity of these mechanisms is the rationale for combining both peptides in one research material. The broader mechanistic background of regenerative peptides is described in the guide to regenerative peptides.

The pre-dissolved pen format is an operational solution for laboratories that want to skip lyophilizate reconstitution: a solution ready for microliter sampling and one batch number for both components. In RUO reagent trade, this is a single material with two chromatographic peaks in the COA, packed in an applicator format known from GLP-1 medicines, but with different documentation and a different intended use.

What is TB-500+BPC-157 PEN – a blend of two regenerative peptides

The One-Peptides PEN contains a blend of two regenerative peptides pre-dissolved in one pen solution: 10 mg TB-500 (the LKKTETQ fragment of Thymosin Beta-4) plus 10 mg BPC-157 (the GEPPPGKPADDAGLV pentadecapeptide). Total peptide mass: 20 mg, with a fixed 1:1 weight ratio.

The solution is ready for sampling and does not require dissolution. Joint sampling means that both peptides remain in a fixed weight ratio; independent control of the concentration of either single peptide is not possible without chromatographic fractionation.

The PEN is a physical-format alternative to the existing SKU “TB-500 5 mg + BPC-157 5 mg blend” in lyophilized vial form. The lyophilizate offers greater flexibility in selecting the starting solution concentration, while the pen eliminates the reconstitution step and doubles the peptide mass per research material (20 mg vs 10 mg).

TB-500 – Thymosin Beta-4 fragment

In RUO reagent trade, TB-500 refers to a synthetic N-terminal fragment of the full Thymosin Beta-4 (Tbeta4) protein with the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ). This fragment contains the actin-binding motif of Tbeta4 (region 17-23) responsible for G-actin sequestration. Molecular mass is approximately ~880 Da; full-length Tbeta4 contains 43 amino acids and has a mass of 4963 Da.

Biochemical class: actin-cytoskeleton regulator. In preclinical work, the mechanism includes sequestration of monomeric G-actin, modulation of endothelial-cell migration and induction of angiogenesis markers. Effects on cardiac muscle regeneration after ischemia (Bock-Marquette et al., 2004) and soft-tissue healing (Goldstein and Hannappel, 2012) have been reported. A full literature overview is available in the article on tissue repair and Thymosin Beta-4.

BPC-157 – Body Protection Compound

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). Its molecular mass is 1419.53 Da. The sequence originates from a fragment of a larger protective protein found in gastric juice.

Biochemical class: cytoprotective peptide and multidirectional modulator. Multiple parallel axes have been reported: NO/cGMP in microcirculation studies, VEGF/VEGFR2 in angiogenesis models (Hsieh et al., 2016), BDNF in CNS models, and tendon and ligament regeneration (Cerovecki et al., 2010). Sikiric et al. (2018) summarize two decades of BPC-157 literature. A full mechanism overview is available in the BPC-157 article.

TB-500+BPC-157 PEN characteristics table

TB-500+BPC-157 PEN synergy mechanism – what the literature says

The idea behind the blend is based on mechanistic complementarity. The two peptides do not compete for the same receptor or signaling pathway. TB-500 dominates the cell-migration layer: G-actin sequestration and cytoskeletal modulation affect the ability of endothelial cells, fibroblasts and myoblasts to move into the injury area. BPC-157 acts multidirectionally: NO/cGMP modulation (microcirculation), VEGF/VEGFR2 (angiogenesis), BDNF and growth factors (tendons, ligaments, peripheral nerves).

The additivity hypothesis assumes parallel effects of both peptides on different phases of the regeneration process. As of early 2026, no randomized clinical trials have been published comparing the blend with each peptide used separately. Individual animal-model studies suggest positive outcomes in combination, but they lack standardized control groups required for definitive conclusions. Synergy remains a mechanistic extrapolation, not a confirmed clinical fact. A direct comparison of both peptides used separately is available in the BPC-157 and TB-500 research comparison.

RUO pen – what it means in reagent trade

The pen is the physical format of the reagent: pre-dissolved peptide in an applicator that enables precise microliter sampling. The format is borrowed from pharmacy (similar to insulin and GLP-1 pens), but the legal status remains different.

TB-500+BPC-157 PEN is not a medicine (no EMA/FDA authorization), is not a dietary supplement and is not intended for injection in humans. Label: “For research use only. Not for human use”.

The difference is in documentation. An RUO pen carries a reagent label and a COA with an HPLC chromatogram and MS confirmation as batch documentation. A pharmaceutical pen (Ozempic, Wegovy, Mounjaro) has a patient leaflet, EMA authorization number and phase III clinical-trial data.

TB-500+BPC-157 PEN – applications in scientific research

• Tendon and ligament injury models – classic rat Achilles tendon rupture model. Assessment of proliferation phase, collagen-fiber organization and biomechanical parameters.
• Skin wound-healing models – incision and second-degree burn models in rodents. Endpoints: wound-closure rate, capillary density, VEGF and CD31 expression.
• Angiogenesis and microcirculation research – HUVEC cultures and in vivo models. Measurement of capillary-like tubular structures, VEGFR2 expression and microcirculatory density.
• Skeletal-muscle injury models – regeneration after mechanical injury or ischemia. Endpoints: satellite-cell activation, MyoD expression and myogenin expression.
• Experiments on regenerative-peptide synergy – projects comparing blend outcomes against single peptides in identical models, with placebo control and group randomization.

One Peptides quality specification

The pen undergoes the same analytical-control process as every research material in the catalogue, with separate verification of both components in one chromatogram.

• HPLC >=98% for each peptide – two main peaks are present in the pen chromatogram (TB-500 and BPC-157), each with purity of at least 98% within its own signal.
• MS confirmation – identity of both peptides confirmed by mass spectrometry (~880 Da for TB-500, 1419.53 Da for BPC-157).
• COA per batch – public certificate of analysis with sequences, masses, salt form, HPLC results, solution concentration, synthesis date and batch number.
• Cold chain 2-8°C – cold-chain handling from synthesis to delivery.
• Batch traceability – batch number on the pen label, invoice and COA.

Details of the QA process, example COAs and a description of each of the five control stages are available under quality testing and certificates.

Working with a pre-dissolved pen in a laboratory protocol

The following description refers to general work with a pre-dissolved pen in the context of a laboratory research reagent. It is not an instruction for administration to humans or animals.

No reconstitution step. The pen contains a ready-made peptide solution, without the need to add bacteriostatic water. The material is available for sampling from the moment the package is opened. A full step-by-step guide for lyophilizates is available in the article how to dissolve peptides – the pen bypasses this stage.

Sampling the solution. Use an insulin syringe or microliter applicator according to the laboratory protocol. Each sample contains a fixed 1:1 TB-500:BPC-157 ratio; independent control of the concentration of one peptide is not possible. Projects requiring separate concentration control require two separate vials of individual peptides.

Stability. After first opening, conservatively 14-28 days at 2-8°C. Freeze-thaw cycles should be strictly avoided. Protect from light and temperatures above 25°C. Disinfect the pen membrane with isopropyl alcohol before each sampling.

The peptide calculator helps calculate the exact sampling volume for the planned peptide mass in an experiment.

Regulatory status and WADA

TB-500 + BPC-157 PEN is a chemical reagent intended exclusively for laboratory research (Research Use Only). Under EU pharmaceutical law, it is not a medicinal product, dietary supplement or food product. It has no EMA or national regulatory authorization. The pen format does not change the legal status; what matters is the reagent composition and batch documentation, not the applicator.

WADA status – prohibited for athletes subject to anti-doping control.

• TB-500 (Thymosin Beta-4) – WADA Prohibited List, category S2 (peptide hormones, growth factors). Prohibited year-round, without exception.
• BPC-157 – WADA Prohibited List (category S0). The substance is not currently prohibited, but its presence in athlete samples is monitored.

The presence of TB-500 means that the entire material must not be used by athletes subject to anti-doping control, regardless of the status of the second peptide. Verification of current status rests with the researcher.

Frequently asked questions

How does the pen differ from the lyophilized blend in a vial?

TB-500+BPC-157 PEN is pre-dissolved and has no reconstitution step. The lyophilized vial requires solvent addition before sampling. The pen contains twice the peptide mass (20 mg vs 10 mg in the 5+5 vial). The lyophilizate provides greater flexibility in selecting the starting solution concentration, while the pen eliminates the dissolution stage.

Can I control TB-500 and BPC-157 concentrations separately from the pen?

No. The solution contains both peptides in a fixed 1:1 ratio, and separation would require chromatographic fractionation. Independent control of individual peptide concentration requires two separate vials of individual peptides.

How long does TB-500+BPC-157 PEN retain activity after first opening?

Conservatively 14-28 days at 2-8°C. The pen is not intended to be frozen or thawed; protect it from light and temperatures above 25°C.

Is there synergy between TB-500 and BPC-157 mechanisms?

The synergy hypothesis is based on mechanistic complementarity. Individual animal-model studies suggest positive outcomes in combination, but randomized clinical trials confirming additivity in humans are lacking. Synergy remains a mechanistic hypothesis.

What is the WADA status of this product?

TB-500 is on the WADA Prohibited List in category S2, year-round. BPC-157 is on the WADA Prohibited List, category S0. The presence of TB-500 means that the entire material must not be used by athletes subject to anti-doping control.

Is TB-500+BPC-157 PEN a medicine?

No. Despite visual similarity to pharmaceutical pens (Ozempic, Wegovy, Mounjaro), the TB-500 + BPC-157 pen is an RUO research reagent, not a medicine. It has no marketing authorization, patient leaflet or registered indications. Label: “For research use only. Not for human use”.

Parent category: Peptides for Regeneration organize RUO reagents associated with recovery-related research contexts.

References

1. Sikiric P et al. (2018). Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy
2. Goldstein AL et al. (2012). Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications
3. Hsieh MJ et al. (2016). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
4. Cerovecki T et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat
5. Bock-Marquette I et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Chemical reagent intended exclusively for laboratory research (Research Use Only). TB-500 + BPC-157 PEN in the One Peptides catalogue is not a medicinal product, dietary supplement or food product, regardless of applicator format. All information in this description is educational and scientific and refers to findings reported in experimental literature; it is not medical advice and does not suggest clinical use. The WADA status of TB-500 (S2 Prohibited List) excludes pen use by athletes subject to anti-doping control.